Interestingly, one of the patients with sustained CR was EGFR-mutant (exon 19 deletion), which is a known predictor of anti-PD1 failure (113), suggesting that NSCLC subtypes that are commonly refractory to ICI might not be resistant to TIL therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.